ScholarIQanswers from OpenAlex & ORCID
Keiichi Fujiwara
ResearcherPublications, citations & collaboration network
Keiichi Fujiwara is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Keiichi Fujiwara have?
ScholarIQindexed works
Keiichi Fujiwara has 659 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Keiichi Fujiwara have?
ScholarIQcitation count
Keiichi Fujiwara has 18,049 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Keiichi Fujiwara?
ScholarIQh-index
Keiichi Fujiwara has an h-index of 61 in OpenAlex.
What is the i10-index of Keiichi Fujiwara?
ScholarIQi10-index
Keiichi Fujiwara has an i10-index of 230 in OpenAlex.
What is the ORCID of Keiichi Fujiwara?
ScholarIQorcid
The ORCID for Keiichi Fujiwara is on the source record.
What is the OpenAlex record for Keiichi Fujiwara?
ScholarIQopenalex
The OpenAlex for Keiichi Fujiwara is on the source record.
What are the most-cited papers on Keiichi Fujiwara?
ScholarIQmost cited works
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martı́n, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää, Frédèric Selle, Jalid Sehouli, Domenica Lorusso, Eva María Guerra Alia, Alexander Reinthaller, Shoji Nagao, Claudia Lefeuvre‐Plesse, Ulrich Canzler, Giovanni Scambia, Alain Lortholary, Frederik Marmé, Pierre Combe, Nikolaus de Gregorio, Manuel Rodrigues, Paul Buderath, Coraline Dubot, Alexander Burges, Benoît You, Éric Pujade-Lauraine, Philipp Harter
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle, Val Gebski, Richard T. Penson, Amit M. Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata, Michael Friedländer, Nicoletta Colombo, Philipp Harter, Keiichi Fujiwara, Isabelle Ray‐Coquard, Susana Banerjee, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Patricia Pautier, Jacob Korach, Tomasz Huzarski, Tomasz Byrski, Patricia Pautier, Michael Friedländer, Philipp Harter, Nicoletta Colombo, Sandro Pignata, Giovanni Scambia, Maria Ornella Nicoletto, Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano, Kian Behbakht, Susan A. Davidson
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Robert L. Coleman, Mark F. Brady, Thomas J. Herzog, Paul Sabbatini, Deborah K. Armstrong, Joan L. Walker, Byoung‐Gie Kim, Keiichi Fujiwara, Krishnansu S. Tewari, David M. O’Malley, Susan A. Davidson, Stephen C. Rubin, Paul DiSilvestro, Karen Basen‐Engquist, Helen Huang, John K. Chan, Nick M. Spirtos, Raheela Ashfaq, Robert S. Mannel
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
Éric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A. Ledermann, Amit M. Oza, Rebecca Kristeleit, Isabelle-Laure Ray-Coquard, Gary Richardson, Cristiana Sessa, Kan Yonemori, Susana Banerjee, Alexandra Léary, Anna V. Tinker, Kyung Hae Jung, Radosław Mądry, Sang‐Yoon Park, Charles Anderson, Fabian Zohren, Ross Stewart, Caimiao Wei, Samuel S. Dychter, Bradley J. Monk
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
Bradley J. Monk, Christine Parkinson, Myong Cheol Lim, David M. O’Malley, Ana Oaknin, Michelle Wilson, Robert L. Coleman, Domenica Lorusso, Paul Bessette, Sharad Ghamande, Athina Christopoulou, Diane Provencher, Emily Prendergast, Fuat Demirkıran, Olga Mikheeva, Oladapo Yeku, Anita Chudecka-Głaz, Michael Schenker, Ramey D. Littell, Tamar Safra, Hung‐Hsueh Chou, Mark A. Morgan, Vít Drochýtek, Joyce N. Barlin, Toon Van Gorp, Frederick R. Ueland, Gabriel Lindahl, Charles Anderson, Dearbhaile Catherine Collins, Kathleen N. Moore, Frederik Marmé, Shannon N. Westin, Iain A. McNeish, Danny Shih, Kevin K. Lin, Sandra Goble, Stephanie Hume, Keiichi Fujiwara, Rebecca Kristeleit